FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to cosmetology, and can be used for treating facial wrinkles. Use and method according to the invention relate to the introduction of botulinum toxin by injection into the face of a subject in a total dose of 80 to 120 units and a total volume of 0.15 ml to 0.30 ml, where brow wrinkles are moderate or pronounced brow wrinkles based on the assessments of the researcher using the facial wrinkle scale (FWS) with maximum frown. Botulinum toxin, which is a neurotoxic component of serotype A botulinum toxin, is injected into 5 points of intramuscular injection.
EFFECT: use of inventions enables to achieve a stable positive effect with good tolerance, enables to avoid side effects - signs of a frozen face - due to a combination of high doses of botulinum toxin and low volumes of injections.
8 cl, 13 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
USE OF BOTULINUM NEUROTOXINS IN TREATMENT | 2018 |
|
RU2766147C2 |
LIQUID COMPOSITION OF BOTULINUM TOXIN FOR TREATING EYEBROW WRINKLES AND LATERAL PERIORBITAL WRINKLES FROM MODERATE TO SEVERE | 2020 |
|
RU2830624C2 |
METHOD OF REDUCING WRINKLES | 1998 |
|
RU2123837C1 |
PROLONGED-RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING POLOXAMER | 2009 |
|
RU2482874C2 |
CLOSTRIDIAL NEUROTOXINS WITH MODIFIED PERSISTENCE | 2009 |
|
RU2524429C2 |
BOTULINUM TOXIN CONTAINING COMPOSITION | 2017 |
|
RU2743746C2 |
COMPOSITION CONTAINING BOTULINUM TOXIN | 2017 |
|
RU2832647C1 |
IMPROVED USE OF BOTULINUM NEUROTOXIN IN THE TREATMENT OF SIALORRHEA | 2018 |
|
RU2778481C2 |
THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
LIQUID COMPOSITION OF NEUROTOXIN STABILIZED WITH TRYPTOPHAN OR TYROSINE | 2017 |
|
RU2741497C2 |
Authors
Dates
2025-03-03—Published
2021-06-04—Filed